Newamsterdam Pharma(NAMS.US)

Company Encyclopedia
View More
name
Newamsterdam Pharma
NAMS.US
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V.
1.896 T
NAMS.USMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking73/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-39.94%E
    • Profit Margin-627.28%E
    • Gross Margin100.00%A
  • Growth ScoreC
    • Revenue YoY4.91%C
    • Net Profit YoY-11.14%D
    • Total Assets YoY79.06%A
    • Net Assets YoY92.17%A
  • Cash ScoreC
    • Cash Flow Margin-15.94%D
    • OCF YoY4.91%C
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreA
    • Gearing Ratio7.42%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $2,719,986.57 in Stock

    NewAmsterdam Pharma's CAO, Louise Frederika Kooij, sold 75,117 shares at $36.21 each, totaling $2,719,986.57, representing an 83.35% decrease in her ownership. Following the sale, she retains 15,000 shares valued at $543,150. Kooij also sold additional shares on December 26th and 24th, totaling over $2.4 million. The stock is currently trading at $35.02, with a market cap of $3.97 billion and a P/E ratio of -17.08. Analysts have mixed ratings, with a consensus average price target of $45.90.

    Market Beat·
    US
    NAMS
    +0.98%
    Market Beat·
    US
    NAMS
    +0.98%

    Chief Accounting Officer Louise Kooij Sells Common Shares of NewAmsterdam Pharma Company NV

    Louise Kooij, Chief Accounting Officer of NewAmsterdam Pharma Company NV, has sold common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published by NewAmsterdam Pharma via EDGAR on December 29, 2025.

    Reuters·
    US
    NAMS
    +0.98%
    Reuters·
    US
    NAMS
    +0.98%

    We're Hopeful That NewAmsterdam Pharma (NASDAQ:NAMS) Will Use Its Cash Wisely

    NewAmsterdam Pharma (NASDAQ:NAMS) has a cash runway of 4.9 years with US$703m in cash and zero debt as of September 2025. The company reduced its cash burn by 6.6% and increased revenue by 4.9%. Analysts predict it will reach breakeven before exhausting its cash reserves. With a market cap of US$4.1b, its cash burn is 3.5% of its value, indicating it can raise funds with minimal dilution. Overall, the company is managing its cash burn well.

    Simplywall·
    US
    NAMS
    +0.98%
    Simplywall·
    US
    NAMS
    +0.98%

    NewAmsterdam Pharma Grants Stock Options to New Hires Under 2024 Inducement Plan

    NewAmsterdam Pharma Company N.V. has granted stock options to two new non-executive hires under its 2024 Inducement Plan. The options cover 40,000 shares at an exercise price of $39.61, vesting over four years. This announcement was made via GlobeNewswire and is for informational purposes only.

    Reuters·
    US
    NAMS
    +0.98%
    Reuters·
    US
    NAMS
    +0.98%

    Owner BCIP Life Sciences Associates LP Files To Sell 32,571 Of NewAmsterdam Pharma Co NV [NAMS]

    BCIP Life Sciences Associates LP, a beneficial owner of NewAmsterdam Pharma Co NV, filed a Form 144 with the SEC to sell 32,571 restricted shares on December 2, 2025. The sale will be brokered by Goldman Sachs & Co. Filing Form 144 allows the owner to sell shares within 90 days. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    NAMS
    +0.98%
    Reuters·
    US
    NAMS
    +0.98%
    © 2026 Longbridge｜Disclaimer